Puretech Health/£PRTC
1D1W1MYTD1Y5YMAX
Capital at risk
About Puretech Health
PureTech Health, trading under the ticker PRTC, is a biotechnology company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. Operating within the healthcare sector, the company leverages its deep expertise in the understanding of disease physiology to advance a pipeline of novel therapies addressing serious medical conditions. Founded in 2015, PureTech Health engages in groundbreaking translational research that bridges the gap between innovative biological insights and potential impactful therapies.
- Ticker
- £PRTC
- Sector
- Health
- Primary listing
- LSE
- Employees
- 90
- Headquarters
- Boston, United States
- Website
- www.puretechhealth.com
Puretech Health Metrics
BasicAdvanced
£293M
-
-£0.34
0.79
-
Price and volume
Market cap
£293M
Beta
0.79
52-week high
£1.44
52-week low
£1.05
Average daily volume
834K
Financial strength
Current ratio
6.587
Quick ratio
6.41
Long term debt to equity
0.594
Total debt to equity
0.653
Interest coverage (TTM)
-2.15%
Profitability
EBITDA (TTM)
-71.907
Gross margin (TTM)
-1,111.74%
Net profit margin (TTM)
-2,355.42%
Operating margin (TTM)
-2,112.34%
Effective tax rate (TTM)
0.76%
Revenue per employee (TTM)
£37,080
Management effectiveness
Return on assets (TTM)
-10.83%
Return on equity (TTM)
-30.85%
Valuation
Price to revenue (TTM)
83.472
Price to book
0.94
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
-4.568
Free cash flow yield (TTM)
-21.89%
Free cash flow per share (TTM)
-0.262
Growth
Revenue change (TTM)
-3.50%
Earnings per share change (TTM)
-319.05%
3-year revenue growth (CAGR)
-33.18%
10-year revenue growth (CAGR)
-8.90%
3-year earnings per share growth (CAGR)
36.30%
10-year earnings per share growth (CAGR)
8.02%
What the Analysts think about Puretech Health
Analyst ratings (Buy, Hold, Sell) for Puretech Health stock.
Analyst projections of the future price of Puretech Health stock.
Bulls say / Bears say
PureTech’s Founded Entity Celea completed a $180 million Series Seed financing led by top‐tier investors, and PureTech retains a 35.4% equity stake plus non‐dilutive royalties and milestone rights, reducing near‐term capital outlay while preserving upside (Reuters).
Celea dosed the first patient in the global Phase 3 SURPASS‐IPF trial in July 2026, marking the start of a pivotal head‐to‐head comparison with pirfenidone that could generate significant clinical and commercial data catalysts (Reuters).
Deupirfenidone received Orphan Drug Designation from both the U.S. FDA and the European Commission in February 2026, granting potential market exclusivity and premium pricing power for the treatment of idiopathic pulmonary fibrosis (Reuters).
PureTech voluntarily delisted its Nasdaq ADSs in May 2026, reducing access for U.S. investors and potentially lowering trading liquidity and valuation support (Reuters).
Deupirfenidone programme accounted for approximately 70% of PureTech’s external R&D expenses (~$31 million in 2025), concentrating pipeline risk on a single asset and heightening the impact of any clinical setback (Reuters).
The $180 million financing RNS cautioned that Celea will require additional funding to fully realise the value of the transferred assets, which may necessitate further capital contributions or dilution for PureTech despite its reserved $70 million commitment (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Puretech Health Financial Performance
Revenues and expenses
Puretech Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.